Zongertinib, an oral therapy shown to have strong responses in patients previously treated for HER2 -mutated non–small cell ...

Boehringer Ingelheim unveiled new data from its top oncology prospect zongertinib, further backing the drug’s prowess in ...

Zongertinib shows promise for treating HER2-mutant non–small cell lung cancer (NSCLC), with significant activity against brain metastases and low interstitial lung disease risk, explains John Heymach, ...

Diliman has identified potential biomarkers or signs that can help with early lung cancer detection with the support of the ...

In patients with advanced squamous non–small cell lung cancer, ivonescimab plus chemo was associated with progression-free ...

Boehringer Ingelheim reported new and updated data from the Beamion LUNG-1 trial evaluating zongertinib in previously treated patients with HER2 (ERBB2)-mutant advanced non-small cell lung cancer ...

Numerous studies conducted by researchers at Dana-Farber Cancer Institute report progress for cancers including head and neck cancer, metastatic breast cancer and lung cancer.

The study found that lower-income, uninsured, and urban and rural patients are less likely to receive robotic surgery for NSCLC. Robotic surgery adoption in the U.S. varies widely by region, with ...

A panelist discusses how prophylactic dermatologic management, including the proactive use of moisturizers, topical steroids, ...

Tumor-infiltrating clonal hematopoiesis (TI-CH) increased the risk of disease recurrence or death among patients with early ...

Activity in preclinical models of ovarian, prostate, and non-small cell lung cancer supports potential utility of OP-3136, a KAT6 inhibitor, in indications beyond breast cancerPatient recruitment ...